WO2002025278A3 - Verfahren zur bestimmung der peptidhormon-aktivitäten oder der steroidhormon-aktivitäten eines materials oder stoffgemisches - Google Patents

Verfahren zur bestimmung der peptidhormon-aktivitäten oder der steroidhormon-aktivitäten eines materials oder stoffgemisches Download PDF

Info

Publication number
WO2002025278A3
WO2002025278A3 PCT/DE2001/003628 DE0103628W WO0225278A3 WO 2002025278 A3 WO2002025278 A3 WO 2002025278A3 DE 0103628 W DE0103628 W DE 0103628W WO 0225278 A3 WO0225278 A3 WO 0225278A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormone
determining
reporter gene
activities
hormone activities
Prior art date
Application number
PCT/DE2001/003628
Other languages
English (en)
French (fr)
Other versions
WO2002025278A2 (de
Inventor
Axel Allera
Ludwig Wildt
Original Assignee
Axel Allera
Ludwig Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axel Allera, Ludwig Wildt filed Critical Axel Allera
Priority to DE10194024T priority Critical patent/DE10194024D2/de
Priority to US10/380,963 priority patent/US20040023264A1/en
Priority to AU2002213808A priority patent/AU2002213808A1/en
Priority to EP01982131A priority patent/EP1325327A2/de
Publication of WO2002025278A2 publication Critical patent/WO2002025278A2/de
Publication of WO2002025278A3 publication Critical patent/WO2002025278A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Bestimmung der Peptidhormon-Aktivitäten oder der Steroidhormon-Aktivitäten eines Materials oder Stoffgemisches, mit: (a) Vorlegen mindestens einer Ausgangszelle mit oder ohne endogene Peptidhormon-Rezeptoren oder Steroidhormon-Rezeptoren; (b) Transfektion der Zelle mit einem spezifischen rekombinanten Reportergen-Konstrukt, das die Fähigkeit besitzt, ein durch die Hormon-Aktivität des Materials induziertes meßbares Produkt zu exprimieren; (c) Einbringen eines zu untersuchenden Materials in die transfizierte Zelle; (d) Herstellung eines leicht bestimmbaren Signal-gebenden Reportergen-Translationsprodukts durch die transfizierte Zelle mittels der induktiven Wirkung des Materials auf den dem Reportergen vorgeschalteten Hormon-reaktiven Promoter; (e) Messen des Reportegen-Translationsprodukts der tranfizierten Zelle und (f) Bestimmen der Hormon-Aktivität des Materials aus dem Meßergebnis.
PCT/DE2001/003628 2000-09-20 2001-09-20 Verfahren zur bestimmung der peptidhormon-aktivitäten oder der steroidhormon-aktivitäten eines materials oder stoffgemisches WO2002025278A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE10194024T DE10194024D2 (de) 2000-09-20 2001-09-20 Verfahren zur Bestimmung der Peptidhormon-Aktivitäten oder der Steroidhormon-Aktivitäten eines Materials oder Stoffgemisches
US10/380,963 US20040023264A1 (en) 2000-09-20 2001-09-20 Method for determining the peptide hormone activities or the steroid hormone activities of a material or substance mixture
AU2002213808A AU2002213808A1 (en) 2000-09-20 2001-09-20 Method for determining the peptide hormone activities or the steroid hormone activities of a material or substance mixture
EP01982131A EP1325327A2 (de) 2000-09-20 2001-09-20 Verfahren zur bestimmung der peptidhormon-aktivitäten oder der steroidhormon-aktivitäten eines materials oder stoffgemisches

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10046647.8 2000-09-20
DE10046647A DE10046647A1 (de) 2000-09-20 2000-09-20 Verfahren zur Bestimmung der Peptidhormon-Aktivitäten oder der Steroidhormon-Aktivitäten eines Materials oder Stoffgemisches

Publications (2)

Publication Number Publication Date
WO2002025278A2 WO2002025278A2 (de) 2002-03-28
WO2002025278A3 true WO2002025278A3 (de) 2002-12-05

Family

ID=7657001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/003628 WO2002025278A2 (de) 2000-09-20 2001-09-20 Verfahren zur bestimmung der peptidhormon-aktivitäten oder der steroidhormon-aktivitäten eines materials oder stoffgemisches

Country Status (5)

Country Link
US (1) US20040023264A1 (de)
EP (1) EP1325327A2 (de)
AU (1) AU2002213808A1 (de)
DE (2) DE10046647A1 (de)
WO (1) WO2002025278A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215111A1 (en) * 2005-06-07 2009-08-27 Veenstra Timothy D Analysis of steroid hormones in thin tissue sections
US20070004045A1 (en) * 2005-06-07 2007-01-04 Xia Xu Analysis of large numbers of estrogens and other steroids and applications thereof
CN113801889B (zh) * 2021-09-18 2023-04-07 中国农业科学院农业质量标准与检测技术研究所 细胞筛选模型及其构建方法和应用、酵母菌及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854004A (en) * 1991-11-25 1998-12-29 Boehringer Ingleheim Gmbh Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path
WO1999016902A1 (en) * 1997-09-30 1999-04-08 University Of Wales College Of Medicine Bioassay for thyroid stimulating antibodies
WO1999041608A2 (en) * 1998-02-12 1999-08-19 Prolifix Limited Interaction between cyclin d1 and steroid receptor co-activators
WO2000037681A1 (en) * 1998-12-18 2000-06-29 American Home Products Corporation BIOASSAY FOR IDENTIFYING ESTROGEN RECEPTOR-β/α SELECTIVE MODULATORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0939810B1 (de) * 1996-07-12 2007-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Transkriptions zwischen faktor-2 tif2
US5728534A (en) * 1996-07-19 1998-03-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular therapeutic agents
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6291194B1 (en) * 2000-07-28 2001-09-18 Taneli Raivio Assay for determination of androgenic or anti-androgenic activity of a serum sample or a test compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854004A (en) * 1991-11-25 1998-12-29 Boehringer Ingleheim Gmbh Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path
WO1999016902A1 (en) * 1997-09-30 1999-04-08 University Of Wales College Of Medicine Bioassay for thyroid stimulating antibodies
WO1999041608A2 (en) * 1998-02-12 1999-08-19 Prolifix Limited Interaction between cyclin d1 and steroid receptor co-activators
WO2000037681A1 (en) * 1998-12-18 2000-06-29 American Home Products Corporation BIOASSAY FOR IDENTIFYING ESTROGEN RECEPTOR-β/α SELECTIVE MODULATORS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARNOLD S F ET AL: "A YEAST ESTROGEN SCREEN FOR EXAMINING THE RELATIVE EXPOSURE OF CELLS TO NATURAL AND XENOESTROGENS", ENVIRONMENTAL HEALTH PERSPECTIVES, XX, XX, vol. 104, no. 5, May 1996 (1996-05-01), pages 544 - 548, XP001026841, ISSN: 0091-6765 *
KNOKE INGRID ET AL: "Significance of the CAG repeat length in the androgen receptor gene (AR) for the transactivation function of an M780I mutant AR.", HUMAN GENETICS, vol. 104, no. 3, March 1999 (1999-03-01), pages 257 - 261, XP002210955, ISSN: 0340-6717 *
SOMMER B ET AL: "Efficient gene transfer into normal skeletal cells using recombinant adenovirus and conjugated adenovirus-DNA complexes.", CALCIFIED TISSUE INTERNATIONAL, vol. 64, no. 1, January 1999 (1999-01-01), pages 45 - 49, XP002210956, ISSN: 0171-967X *

Also Published As

Publication number Publication date
US20040023264A1 (en) 2004-02-05
WO2002025278A2 (de) 2002-03-28
DE10194024D2 (de) 2003-10-02
AU2002213808A1 (en) 2002-04-02
EP1325327A2 (de) 2003-07-09
DE10046647A1 (de) 2002-03-28

Similar Documents

Publication Publication Date Title
Leung et al. Over-expression of FoxM1 stimulates cyclin B1 expression
Lemberger et al. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids.
Balaguer et al. Reporter cell lines are useful tools for monitoring biological activity of nuclear receptor ligands
Murayama et al. Retracted: Transrepression by a liganded nuclear receptor via a bHLH activator through co‐regulator switching
Waters et al. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform
Sedlák et al. Two panels of steroid receptor luciferase reporter cell lines for compound profiling
Pike et al. Structural aspects of agonism and antagonism in the oestrogen receptor
Bahat et al. StAR enhances transcription of genes encoding the mitochondrial proteases involved in its own degradation
Jin et al. Human vitamin D receptor-dependent transactivation in Saccharomyces cerevisiae requires retinoid X receptor.
Nomura et al. Gene regulation and physiological function of placental leucine aminopeptidase/oxytocinase during pregnancy
Bryś et al. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies
Rochefort et al. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells
WO2002025278A3 (de) Verfahren zur bestimmung der peptidhormon-aktivitäten oder der steroidhormon-aktivitäten eines materials oder stoffgemisches
Dayan et al. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor α
Gehm et al. EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway
Mishra et al. X-linked lymphocyte regulated gene 5c-like (Xlr5c-like) is a novel target of progesterone action in granulosa cells of periovulatory rat ovaries
Byun et al. Repression of Transcriptional Activity of Estrogen Receptor a by α Cullin3/SPOP Ubiquitin E3 Ligase Complex
Bapat et al. Full-length estrogen receptor α and its ligand-binding domain adopt different conformations upon binding ligand
Hofman et al. Apparent coactivation due to interference of expression constructs with nuclear receptor expression
Knutson et al. Characterization of the human Megalin/LRP-2 promoter in vitro and in primary parathyroid cells
Thevis et al. Annual banned‐substance review: the Prohibited List 2008—analytical approaches in human sports drug testing
Latini et al. Inhibitory effect of pituitary adenylate cyclase activating polypeptide on the initial stages of rat follicle development
Foley et al. Regulation of parathyroid hormone-related protein gene expression in murine keratinocytes by E1A isoforms: a role for basal promoter and Ets-1 site
Hofman et al. Coactivation of an endogenous progesterone receptor by TIF2 in COS-7 cells
Katso et al. Evaluation of cell-based assays for steroid nuclear receptors delivered by recombinant baculoviruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001982131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10380963

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001982131

Country of ref document: EP

REF Corresponds to

Ref document number: 10194024

Country of ref document: DE

Date of ref document: 20031002

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10194024

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: JP